☆ 4.5 Article

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

JOURNAL OF HEADACHE AND PAIN (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study

Fabrizio Vernieri et al.

Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study

Fabrizio Vernieri et al.

Summary: This study found that in patients with chronic migraine, unilateral pain, a good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Piero Barbanti et al.

Summary: This study investigated the effectiveness, safety, and tolerability of fremanezumab in a real-life population of high-frequency episodic or chronic migraine patients. The results showed that fremanezumab was effective in reducing migraine days, headache days, analgesic intake, and improving quality of life in both types of migraine. Younger age emerged as a potential predictor for positive treatment response.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

Messoud Ashina et al.

Summary: This study investigated the safety and efficacy of eptinezumab for patients with migraine and two-to-four previous preventive treatment failures, showing significant migraine preventive effects compared to placebo.

LANCET NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

The ultimate guide to the anti-CGRP monoclonal antibodies galaxy

Davide Mascarella et al.

Summary: Anti-CGRP monoclonal antibodies have shown remarkable efficacy and safety in the treatment of migraines. Real-world studies have provided additional insights beyond clinical trials, confirming the effectiveness of these revolutionary medications.

NEUROLOGICAL SCIENCES (2022)

添加到收藏夹

Article Clinical Neurology

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Piero Barbanti et al.

Summary: This study investigates the predictors of response to antiCGRP mAbs in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). The results show that in HFEM, unilateral pain + unilateral cranial autonomic symptoms are positively associated with >= 50% response. In CM, allodynia + unilateral pain, unilateral cranial autonomic symptoms are positively associated with >= 50% response, while obesity is negatively associated with >= 50% response. This study is important for predicting the response of migraine patients to antiCGRP mAbs.

JOURNAL OF HEADACHE AND PAIN (2022)

添加到收藏夹

Article Clinical Neurology

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Piero Barbanti et al.

Summary: Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

HEADACHE (2021)

添加到收藏夹

Article Clinical Neurology

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fabrizio Vernieri et al.

Summary: In real-life settings, galcanezumab showed significant effectiveness in preventing HFEM and CM by reducing the number of migraine days and headache intensity, with good safety and tolerability. Patients who responded well to galcanezumab tended to have normal weight and a history of fewer failed preventive treatments.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti et al.

Summary: In a real-world setting, erenumab showed long-term effectiveness, safety, and tolerability in patients with high-frequency episodic migraine or chronic migraine with multiple prior preventive treatment failures. Positive predictors of responsiveness included allodynia in high-frequency episodic migraine, male sex, and baseline migraine frequency in chronic migraine, while negative predictors included psychiatric comorbidities and prior treatment failures in chronic migraine patients.

HEADACHE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial

Paul K. Winner et al.

Summary: This study shows that intravenous eptinezumab can reduce the time to headache and symptom relief during a moderate to severe migraine attack without serious adverse events.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Clinical Neurology

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Messoud Ashina et al.

Summary: Fremanezumab showed sustained efficacy for up to 6 months and was well tolerated in patients with episodic or chronic migraine who had inadequate response to multiple preventive medications. Patients receiving monthly or quarterly doses of fremanezumab experienced improvements in migraine days, disability scores, and other migraine-related symptoms with low rates of adverse events leading to discontinuation.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Clinical Neurology

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina et al.

CEPHALALGIA (2020)

添加到收藏夹

Article Clinical Neurology

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

Richard B. Lipton et al.

NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies

Danuta Szkutnik-Fiedler

PHARMACEUTICS (2020)

添加到收藏夹

Article Clinical Neurology

Erenumab: from scientific evidence to clinical practicethe first Italian real-life data

Piero Barbanti et al.

NEUROLOGICAL SCIENCES (2019)

添加到收藏夹

Article Medicine, General & Internal

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari et al.

LANCET (2019)

添加到收藏夹

Article Clinical Neurology

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Vladimir Skljarevski et al.

CEPHALALGIA (2018)

添加到收藏夹

Article Clinical Neurology

A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects

Orit Cohen-Barak et al.

CEPHALALGIA (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial

David W. Dodick et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Clinical Neurology

Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial

Virginia L. Stauffer et al.

JAMA NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Uwe Reuter et al.

LANCET (2018)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart Tepper et al.

LANCET NEUROLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Fremanezumab for the Preventive Treatment of Chronic Migraine

Stephen D. Silberstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Clinical Neurology

The International Classification of Headache Disorders, 3rd edition (beta version)

Andre Bes et al.

CEPHALALGIA (2013)

添加到收藏夹

Article Clinical Neurology

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

Eva Cernuda-Morollon et al.

NEUROLOGY (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.